Skip to content

A Randomized, Parallel-Controlled, Single-Center Clinical Trial on the Efficacy and Safety of Chinese Herbal Fever-Reducing Patch in Combination with Pediatric Chishao Qingre Granules for the Treatment of Pediatric External-Sense Fever

A Randomized, Parallel-Controlled, Single-Center Clinical Trial on the Efficacy and Safety of Chinese Herbal Fever-Reducing Patch in Combination with Pediatric Chishao Qingre Granules for the Treatment of Pediatric External-Sense Fever

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001258
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper respiratory tract infection

Interventions

Treatment group:Conventional treatment plus Chinese herbal fever-reducing patch
Control Group:Conventional Treatment

Sponsors

Nanyang City First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Age: 1 year = Age = 14 years. 2.:. Western Medical Diagnosis: Meets the diagnostic criteria for acute upper respiratory tract infections in children as specified in "Pediatrics." 3.:. Traditional Chinese Medicine Differentiation: Meets the diagnostic criteria for exogenous fever with wind-heat pattern in children as specified in the "Guidelines for Clinical Research of New Chinese Herbal Drugs." 4.:,. Compliance: The child and legal guardian are able to understand and adhere to the study requirements, cooperate with treatment, and follow-up. 5.:. Informed Consent: The legal guardian signs a written informed consent form""

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the above inclusion criteria. 2. Those with fever lasting more than 72 hours (3 days). 3. Those allergic to the ingredients of Xiao'er Diquqingre Granules or traditional Chinese medicine fever-reducing plaster. 4. Those with severe primary diseases of the heart, liver, kidneys, digestive system, hematopoietic system, or severe malnutrition. 5. Legal representatives who do not agree to participate in the study.

Design outcomes

Primary

MeasureTime frame
Body Temperature;

Secondary

MeasureTime frame
Onset time (time to initial temperature decrease);Time to normal body temperature;Traditional Chinese Medicine syndrome score at 72 hours post-treatment;Comprehensive efficacy assessment (cured/markedly effective/effective/ineffective);Overall clinical response rate;Ibuprofen suspension usage;

Countries

China

Contacts

Public ContactZhang Shaohua

Nanyang City First People's Hospital

13838761806@163.com13838761806

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026